Physician profile
Thomas Romano
NPI 1023031184
$130,985.00
in general payments reported to CMS, 2019-2025
26 companies · $450 in 2025
The $450 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $17K · 2021: $25K · 2022: $37K · 2023: $150 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $350 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $350.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $73,030.56 | 2019-2025 | |
| Amgen INC. | $39,062.75 | 2019-2022 | |
| Celgene Corporation | $10,496.53 | 2019 | |
| Ucb, INC. | $1,858.84 | 2019-2022 | |
| Horizon Therapeutics Plc | $822.34 | 2019-2022 | |
| Glaxosmithkline, LLC. | $817.19 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $684.68 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $473.34 | 2020-2022 | |
| Fidia Pharma USA INC. | $437.71 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $400.68 | 2019-2022 | |
| Pfizer INC. | $378.75 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.00 | 2020-2025 | |
| Genentech USA, INC. | $297.56 | 2019 | |
| United Therapeutics Corporation | $278.90 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $277.67 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $244.84 | 2021-2022 | |
| Genzyme Corporation | $234.57 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $200.62 | 2021-2022 | |
| Zoll Medical Corporation | $150.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $143.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $114.08 | 2021-2022 | |
| Janssen Biotech, INC. | $98.54 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $86.44 | 2019-2022 | |
| Ibsa Pharma INC. | $37.25 | 2021 | |
| Dexcom, INC. | $17.75 | 2021 | |
| Sobi, INC | $14.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Romano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.